BMI View: The Brazilian pharmaceutical market remains the most attractive to multinational
pharmaceutical companies in Latin America. The expansion of healthcare coverage, driven by local
authorities, presents significant revenue-generating opportunities for drugmaker ..."
BMI View: New legislation encouraging generic drug use is an important step in bringing high quality
medicines to the Chilean market and eventually improving access to medicines in the country. The tightened
bioequivalent regulations will boost genuine medicine sales ..."
BMI View: Peru will offer longer-term growth opportunities to foreign pharmaceutical companies.
Although per capita medicine spending in the country is among the lowest in Latin America,
pharmaceutical companies can generate rapid sales growth due to the lack of manda ..."
BMI View: Argentina's pharmaceutical industry has been relatively competitive in the Latin America
region due to skilled professionals, low-cost operations and export-oriented policies. However, public
incentives in the Argentinean biotechnology sector remain scant, a ..."
BMI View: As BMI's July 2013 forecast for government drug pricing pressure to increase in Colombia has
materialised, we now believe drugmakers' revenue streams will continue to be constrained over the coming
years. On the positive side, we expect volume sales will be ..."
BMI View: Brazil's traditional commitment to healthcare improvement and growing middle-class
population present significant revenue-generating opportunities for multinationals in the country. The
Brazilian pharmaceutical market is now an integral part of all large pha ..."
BMI View: The economic downturn and limited domestic market growth have forced Chilean drugmakers
to seek better returns abroad. Chile's regional leading business environment has ensured local companies
enjoy favourable external financing resources to support their in ..."
BMI View: Compared with other second tier markets in Latin America, Peru's pharmaceutical market has
generated the least interest among multinationals. Its low per capita spending on drugs, weakening
currency, and local authorities' bias towards non-equivalent generic ..."
BMI View: We continue to expect steady growth of the Colombian pharmaceutical market over the five
years to 2017. Volume demand - from both demographic and epidemiological points of view - will continue
to play an important role in the market development. On the down ..."
BMI View: Domestic pharmaceutical companies in Argentina are more competitive than many other Latin
American drugmakers. Unlike neighbouring country Brazil, which can lure multinationals to supply
advanced technologies in exchange for a secure market share in its attr ..."